Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my 2013 interview with him here), are already in the public domain, but other big developments […]
Big Changes Unfolding at Advanced Cell Technology (ACTC) Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
How is the FDA doing on regulating stem cell treatments in the US and what should it do looking to the future? Please take the 4 polls below to indicate your thoughts and also add comments to tell us more about your thinking on these key questions.
4 New Polls on FDA Regulation of Stem Cells Read More »
One of the big stem cell-related stories of 2013 was the controversy over the Stamina Foundation in Italy and its potential use of largely untested stem cell products on patients, including mostly children. The winner of my 2013 Stem Cell Person of the Year Award was Dr. Elena Cattaneo and one reason she won was the courage
Nature Slams Controversial Stamina Foundation: A Dangerous Situation Continues Read More »
In the interview below I talk with Dr. Masayo Takahashi, who is leading a team conducting the first ever in-human clinical study based on iPS cells. The work began with patient enrollment on Aug. 1, 2013 in Japan. Masaya Takahashi background 1. Can you tell us a bit about your background? As an M.D./Ph.D. and
Masayo Takahashi Interview on iPS cells, clinical studies, & more Read More »
Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made
J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »
One of the most concerning new trends in the stem cell arena is the explosive growth of chains of for-profit stem cell clinics in the US including Stem MD. This kind of franchising of stem cell for-profit operations deeply concerns me in terms of its potential risks to increasing numbers of patients and to the
Claims of Stem Cell Cures by Clinic Chain, Stem MD Read More »
Who reads this stem cell blog? I recently did a poll that allows readers of this blog to self-identify themselves in terms of who they are. I included 20 categories and someone picked all of them at least once. I was happy to get more than 220 responses and the results were quite surprising to
Surprising Poll Results on Stem Cell Blog Readership Read More »
I’ve been working on a stem cell outreach program for education (SCOPE) the last couple years. The mission of SCOPE is “stem cells not lost in translation”. What is SCOPE? I’ve got a white paper up on key facts and considerations for stem cells in dozens of languages. More than 120,000 people across the globe
Stem Cell Outreach Success in Spanish: ¿Qué son las células madre? Read More »
This past year of 2013 was a wild one for stem cells. 2014 looks to be just as cool and fun as 2013 as well as having at least as many freaky moments. What’s in store? Here’s your preview to whet your appetite for stem cell info, much you cannot get elsewhere including unique blog
2014 Stem Cell Blog Teasers Read More »